Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury

Diabetes

Volumn 54, Issue 1, 2005, Pages 146-151

  Bose, Amal K ^a   Mocanu, Mihaela M ^a   Carr, Richard D ^b   Brand, Christian L ^b   Yellon, Derek M ^a  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^b NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; GLUCAGON LIKE PEPTIDE 1; PROTEIN BAD;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; IN VITRO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; REPERFUSION INJURY; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; BLOOD PRESSURE; BUTADIENES; CHROMONES; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HEART RATE; INSULIN; MALE; MAP KINASE SIGNALING SYSTEM; MORPHOLINES; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; NITRILES; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 12144260853     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.54.1.146     Document Type: Article

References (36)

1. Deacon CF, Hughes TE, Holst JJ: Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes 47:764-769, 1998
2. Wei Y, Mojsov S: Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett 358:219-224, 1995
3. Holz GG, Leech CA, Habener JF: Activation of a cAMP-regulated Ca(2+)-signalling pathway in pancreatic beta-cells by the insulinotropic hormone glucagon-like peptide-1. J Biol Chem 270:17749-17757, 1995
4. Kwon G, Pappan KL, Marshall CA, Schaffer JE, McDaniel ML: Cyclic AMP dose-dependently prevents palmitate-induced apoptosis by both PKA- and cAMP-GEF-dependent pathways in beta-cells. J Biol Chem 279:8938-8945, 2003
5. Nishihara H, Kizaka-Kondoh, S, Insel PA, Eckmann L: Inhibition of apoptosis in normal and transformed intestinal epithelial cells by cAMP through induction of inhibitor of apoptosis protein (IAP)-2. Proc Natl Acad Sci U S A 100:8921-8926, 2003
6. Hui H, Nourparvar A, Zhao X, Perfetti R: Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5′-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 144:1444-1455, 2003
7. Vila Petroff MG, Egan JM, Wang X, Sollott SJ: Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes. Circ Res 89:445-452, 2001
8. Barragan JM, Rodriguez RE, Blazquez E: Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats. Am J Physiol 266:E459-E466, 1994
9. Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME, Hollenberg AN, Baggio L, Saper CB, Drucker DJ, Elmquist JK: Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 110:43-52, 2002
10. Gros R, You X, Baggio LL: Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology 144:2242-2252, 2003
11. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, Shannon RP: Effects of glucagon-like peptide-1 in patients with acute myocardlal infarction and left ventricular dysfunction after successful reperfusion. Circulation 109:962-965, 2004
12. Buteau J, Roduit R, Susini, S, Prentki M: Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia 42:856-864, 1999
13. Hausenloy DJ, Yellon DM: New directions for protecting the heart against ischemia-reperfusion injury: targeting the reperfusion injury salvage kinase (RISK)-pathway. Cardiovasc Res 61:448-460, 2004
14. Tong H, Chen W, Steenbergen C, Murphy E: Ischemic preconditioning activates phosphatidylinositol-3-kinase upstream of protein kinase C. Circ Res 87:309-315, 2000
15. Mocanu MM, Bell RM, Yellon DM: PI3 kinase and not p44/42 appears to be implicated in the protection conferred by ischemic preconditioning. J Mol Cell Cardiol 34:661-668, 2002
16. Redondo A, Trigo MV, Acitores A, Valverde I, Vulanueva-Penacarrillo ML: Cell signalling of the GLP-1 action in rat liver. Mol Cell Endocrinol 204:43-50, 2003
17. Jonassen AK, Brar BK, Mjos OD, Sack MN, Latchman DS, Yellon DM: Insulin administered at reoxygenation exerts a cardioprotective effect in myocytes by a possible anti-apoptotic mechanism. J Mol Cell Cardiol 32:757-764, 2000
18. Raufman JP, Singh L, Singh G, Eng J: Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas. J Biol Chem 267:21432-21437, 1992
19. Barragan JM, Rodriguez RE, Eng J, Blazquez E: Interactions of exendin (9-39) with the effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure and heart rate in rats. Regul Pept 67:63-68, 1996
20. Nauck MA, Heimesaat MM, Behle K, Holst JJ, Nauck MS, Ritzel R, Hufner M, Schmiegel WH: Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 87:1239-1246, 2002
21. Meneilly GS, McIntosh CH, Pederson RA, Habener JF, Gingerich R, Egan JM, Elahi D: Glucagon-like peptide-1 (7-37) augments insulin-mediated glucose uptake in elderly patients with diabetes. J Gerontol A Biol Sci Med Sci 56:M681-M685, 2001
22. Urusova IA, Farilla L, Hui H, D'Amico E, Perfetti R: GLP-1 inhibition of pancreatic islet cell apoptosis. Trends Endocrinol Metab 15:27-33, 2004
23. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ: Glucagon-like peptide-1 receptor signalling modulates beta cell apoptosis. J Biol Chem 278:471-478, 2003
24. Zha J, Harad H, Yang E, Jocke IJ, Korsmeyer SJ: Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 87:619-628, 1996
25. Bers DM, Ziolo MT: When is cAMP not cAMP? Effects of compartmentalization. Circ Res 89:373-375, 2001
26. Houslay MD, Adams DR: PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling, cross talk, desensitization and compartmentilization. Biochem J 370:1-18, 2003
27. Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ: Glucagon-like peptide-1 undergoes differential tissue specific metabolism in the anesthetized pig. Am J Physiol 271:E458-E464, 1996
28. Barragan JM, Eng J, Rodriguez R, Blazquez E: Neural contribution to the effect of glucagon-like peptide-1 (7-36) amide on arterial blood pressure in rats. Am J Physiol 277:E784-E791, 1999
29. Jonassen AK, Sack MN, Mjos OD, Yellon DM: Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ Res 89:1191-1198, 2001
30. Baines CP, Wang L, Cohen MV, Downey JM: Myocardial protection by insulin is dependent on phosphatidylinositol 3-kinase but not protein kinase C or KATP channels in the isolated rabbit heart. Basic Res Cardiol 94:188-198, 1999
31. Malmberg K, Norhammar A, Ryden L, DIGAMI study: Insulin treatment post myocardial infarction: the DIGAMI study. Adv Exp Med Biol 498:279-284, 2002
32. Diaz R, Paolasso EA, Piegas LS, Tajer CD, Moreno MG, Corvalan R, Isea JE, Romero G: Metabolic modulation of acute myocardial infarction: the ECLA Collaborative Group. Circulation 98:2227-2234, 1998
33. Kavianipour M, Ehlers MR, Malmberg K, Ronquist G, Ryden L, Wikstrom G, Gutniak M: Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium. Peptides 24:569-578, 2003
34. Cotran RS, Kumar V, Robbins SL: Robbins' Pathological Basis of Disease. 5th ed. Philadelphia, WB Saunders, 1994, p. 473-476
35. Deacon CF, Wamberg S, Bje P, Hughes TE, Holst JJ: Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal -induced incretin secretion in dogs. J Endocrinol 172:355-362, 2002
36. Hansotia T, Baggio LL, Delmeire D, Hinke SA, Yamada Y, Tsukiyama K, Seino Y, Holst JJ, Schuit F, Drucker DJ: Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the gluoregulatory actions of DPPW inhibitors. Diabetes 53:1326-1335, 2004